160 related articles for article (PubMed ID: 36597972)
21. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
22. Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
Loftus EV; Colombel JF; Schreiber S; Randall CW; Regueiro M; Ali T; Arendt C; Coarse J; Spearman M; Kosutic G
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1753-1762. PubMed ID: 27464588
[TBL] [Abstract][Full Text] [Related]
23. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
[TBL] [Abstract][Full Text] [Related]
24. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
26. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
27. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
[TBL] [Abstract][Full Text] [Related]
28. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
29. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
30. Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report.
Horai Y; Ishikawa H; Iwanaga N; Izumi Y; Matsuoka Y; Miura S; Kawakami A
J Clin Pharm Ther; 2020 Oct; 45(5):1179-1182. PubMed ID: 31990069
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
[TBL] [Abstract][Full Text] [Related]
32. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.
Martín-Varillas JL; Calvo-Río V; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Garfella MH; Pascual EV; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; Salom D; Ortego N; García-Serrano JL; Callejas-Rubio JL; Herreras JM; García-Aparicio Á; Maíz O; Blanco A; Torre I; Díaz-Valle D; Pato E; Aurrecoechea E; Caracuel MA; Gamero F; Minguez E; Carrasco-Cubero C; Olive A; Vázquez J; Ruiz-Moreno O; Manero J; Muñoz-Fernández S; Martinez MG; Rubio-Romero E; Toyos-Sáenz de Miera FJ; López Longo FJ; Nolla JM; Revenga M; González-Vela C; Loricera J; Atienza-Mateo B; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Ophthalmology; 2018 Sep; 125(9):1444-1451. PubMed ID: 29602570
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
[TBL] [Abstract][Full Text] [Related]
34. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
[TBL] [Abstract][Full Text] [Related]
36. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
[TBL] [Abstract][Full Text] [Related]
37. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
38. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome.
Bosch PC
Eur Urol; 2018 Nov; 74(5):623-630. PubMed ID: 30072210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
